2018
Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients
Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, Fiellin DA, Becker WC. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug And Alcohol Dependence 2018, 192: 371-376. PMID: 30122319, PMCID: PMC7106601, DOI: 10.1016/j.drugalcdep.2018.05.033.Peer-Reviewed Original ResearchConceptsLong-term opioid therapyIllicit drug useUrine drug testsDrug useOpioid therapyWhite racePositive urine drug testDrug testsMonths of treatmentElectronic medical recordsWhite patientsChronic painPatient raceMedical recordsPatientsLogistic regressionOpioidsRacial disparitiesDrug testingCocaineCannabisTherapyCliniciansDiscontinuationPain
2011
Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System
Ohl M, Lund B, Belperio PS, Goetz MB, Rimland D, Richardson K, Justice A, Perencevich E, Vaughan-Sarrazin M. Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System. AIDS And Behavior 2011, 17: 250-259. PMID: 22205324, PMCID: PMC5009625, DOI: 10.1007/s10461-011-0107-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCD4 Lymphocyte CountChildChild, PreschoolDelivery of Health CareDiffusion of InnovationFemaleHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHIV Integrase InhibitorsHumansInfantInfant, NewbornMaleMiddle AgedMultivariate AnalysisOdds RatioPatient Acceptance of Health CarePyrrolidinonesRaltegravir PotassiumResidence CharacteristicsRetrospective StudiesRural Health ServicesRural PopulationSurveys and QuestionnairesUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransViral LoadYoung AdultConceptsHIV therapyEqual access healthcare systemNovel HIV therapiesRetrospective cohort studyFirst HIV integrase inhibitorRural-urban variationRaltegravir therapyCohort studyPatient characteristicsMultivariable analysisHIV integrase inhibitorsClinical indicationsRural residenceFDA approvalTherapyIntegrase inhibitorsUrban residenceRural personsHealthcare systemRaltegravirUrban personsDaysRural areasHIVResidence